Compare DexCom, Inc. (DXCM) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Tesla, Inc. — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Tesla, Inc. trades at $382.6 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 46.5× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Tesla, Inc. for 88 Days on average.
| DXCM | TSLA | |
|---|---|---|
Market Cap | $31.86B | $1.48T |
Volume | 3,607,070 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $489.88 |
52-Week Low | $54.84 | $298.16 |
Typical Hold Time | 62 Days | 88 Days |
Enterprise Value | $31.32B | $1.45T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Tesla (TSLA) trades at $382.70, up 1.35% today, with a bullish technical signal from moving averages but mixed oscillators. The stock faces high valuation multiples (P/E 347.22, P/S 12.8) amid declining profitability, with net income margin falling to 3.67% in 2025. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, though Q2 2026 earnings missed expectations.
Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and competitive pressures. The consensus price target of $441.36 suggests upside, but investors must weigh high valuation, margin compression, and volatile cash flows. Key catalysts include robotaxi progress and demand recovery, while risks involve execution delays and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
